Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Dermatologic 1

Conditions

Neoplasms 4Breast Neoplasms 4Melanoma 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Healthy Participants 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Head and Neck Neoplasms 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Advanced Solid Malignancies 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasms × Digoxin × Clear all
NCT02740712 2023-06-09

DDI

pharmaand GmbH

Phase 1 Completed
17 enrolled
Tumor-Agnostic

Neoplasms

NCT02106845 2019-06-07

Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.

Bayer

Phase 1 Completed
42 enrolled
Tumor-Agnostic

Neoplasms

NCT01517399 2019-02-12

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Daiichi Sankyo

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

NCT01765569 2015-09-23

A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Hoffmann-La Roche

Phase 1 Completed
29 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡